[0042][0043]Angiogenin as a diagnostic or prognostic biomarker and drug target in age-related macular degeneration[0044]The present invention relates to the quantification of various soluble proteins, including angiogenin in aqueous humor and plasma of patients with AMD. The invention further describes the role of angiogenin in the pathogenesis, progression of AMD. Hence, the level of angiogenin serves as a diagnostic and/or prognostic marker in AMD. Angiogenin modulators administered in the form of either intra-vitreal injection or topical solution to patients suffering from AMD can cause the required changes in the levels of angiogenin along with improved prognosis. The invention discloses the quantification of soluble proteins, which is useful for simultaneous detection and quantification of angiogenin along with other molecular factors associated with AMD. The invention also highlights that plausibility of modulating angiogenin function in the management of AMD. (FIGURES 1 and 2)
